
Home » GPC BIOTECH BEGINS SATRAPLATIN/XELODA TRIAL
GPC BIOTECH BEGINS SATRAPLATIN/XELODA TRIAL
May 16, 2006
GPC Biotech has initiated a Phase I study evaluating the company's lead drug candidate, satraplatin, in combination with Xeloda (capecitabine) in patients with advanced solid tumors.
The open-label study is being conducted at Northwestern University Medical Center in Chicago. The trial is expected to enroll up to 24 patients.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
10Mar
-
16Mar
-
18Mar
-
23Mar
-
30Mar
-
06Apr